Document Detail

Influence of aspirin on the clinical outcomes of 103 anti-phospholipid antibodies-positive patients.
MedLine Citation:
PMID:  18089677     Owner:  NLM     Status:  MEDLINE    
One hundred and three consecutive asymptomatic anti-phospholipid (aPL) antibody-positive carriers, taking aspirin (n=75) or not (n=28), were studied retrospectively to determine whether aspirin could provide primary prevention of anti-phospholipid syndrome (APS) symptoms. All patients positive for anti-cardiolipin antibodies (aCL; >25 UGPL or UMPL) and/or lupus anti-coagulant were followed for a mean of 64+/-24.7 months.Among aPL-positive patients, 37 had systemic lupus erythematosus (SLE), 20 had prolonged activated partial thromboplastin times, 19 had other connective tissue diseases, 16 had autoimmune thrombocytopenia (AIT), 11 had diverse diseases. Nineteen patients experienced thrombotic event(s) during follow-up. Clinical features, biological parameters and hydroxychloroquine use were comparable for the two groups, but thrombotic events differed (log-rank test; P=0.02). Four of the 10 SLE patients not taking aspirin developed thrombosis compared with 3/27 SLE patients taking aspirin (log-rank test; P=0.03). Anti-phospholipid -positive patients with AIT developed fewer thromboses while taking aspirin (log-rank test; P=0.01). In conclusion, aPL-positive SLE and AIT patients should take aspirin to prevent APS manifestations. Prospective therapeutic trials are needed to confirm aspirin's prophylactic role in such patients.
T Hereng; M Lambert; E Hachulla; M Samor; S Dubucquoi; C Caron; D Launay; S Morell-Dubois; V Queyrel; P-Y Hatron
Related Documents :
16534157 - Cardiovascular involvement in systemic lupus erythematosus: an autopsy study of 27 pati...
10502127 - Delayed onset of systemic lupus erythematosus in patients with "full-house" nephropathy.
9283997 - Antithymocyte globulin for a patient with systemic lupus erythematosus complicated by s...
9622037 - Anticardiolipin antibodies in clinical conditions associated with a risk of thrombotic ...
20525297 - Oral lichen planus: a retrospective study of 110 brazilian patients.
16925087 - Atlantoaxial stabilization with the use of c1-3 lateral mass screw fixation. technical ...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Lupus     Volume:  17     ISSN:  0961-2033     ISO Abbreviation:  Lupus     Publication Date:  2008 Jan 
Date Detail:
Created Date:  2007-12-19     Completed Date:  2008-04-29     Revised Date:  2011-03-11    
Medline Journal Info:
Nlm Unique ID:  9204265     Medline TA:  Lupus     Country:  England    
Other Details:
Languages:  eng     Pagination:  11-5     Citation Subset:  IM    
Department of Internal Medicine, University Hospital of Lille, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antibodies, Anticardiolipin / blood*
Antiphospholipid Syndrome / complications,  drug therapy*,  immunology,  mortality
Aspirin / therapeutic use*
Disease Progression
Fibrinolytic Agents / therapeutic use*
Follow-Up Studies
Lupus Coagulation Inhibitor / blood*
Lupus Erythematosus, Systemic / complications,  drug therapy,  immunology,  mortality
Middle Aged
Purpura, Thrombocytopenic, Idiopathic / complications,  drug therapy*,  immunology,  mortality
Retrospective Studies
Thrombosis / immunology,  mortality,  prevention & control*
Time Factors
Treatment Outcome
Reg. No./Substance:
0/Antibodies, Anticardiolipin; 0/Fibrinolytic Agents; 0/Lupus Coagulation Inhibitor; 50-78-2/Aspirin
Comment In:
Curr Rheumatol Rep. 2009 Feb;11(1):1-2   [PMID:  19171105 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Review: vitamin D, immunity and lupus.
Next Document:  Proteomic analysis of autoantibodies in neuropsychiatric systemic lupus erythematosus patient with w...